Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus
The Oncologist · 2026
DOI: 10.1093/oncolo/oyaf439 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Bin Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Bevacizumab, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission Health Industry Clinical Research Special, Shanghai Municipal Science and Technology Commission, Naval Medical University and Eastern Hepatobiliary Surgery Hospital.
Abstract (Originalsprache)
Background
Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT. Patients and Methods This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).
Results
Baseline characteristics showed similar distributions between the two groups. SBRT + Sin + Bev group showed a significant increase in both median OS (18.9 vs 9.3 months, P < .001), median PFS (9.1 vs 4.7 months, P = .0015), and ORR (64.6% vs 26.3%, P = .031) compared to Sin + Bev group. TRAEs in SBRT + Sin + Bev group were mostly manageable and acceptable compared to Sin + Bev group. Multivariate analysis confirmed that SBRT + Sin + Bev was an independent prognostic factor for better OS (P < .001) and better PFS (P < .001).
Conclusion
SBRT combined with sintilimab plus bevacizumab appears to improve treatment efficacy and demonstrates a favorable safety and feasibility profile for HCC with PVTT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
- Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
ORCID-Profile: Xingsheng Lu
Förderung
- Shanghai Municipal Health Commission Health Industry Clinical Research Special
- Shanghai Municipal Science and Technology Commission
- Naval Medical University and Eastern Hepatobiliary Surgery Hospital
- Clinical Key Disease Diagnosis and Treatment Technology Project of Suzhou Municipal Health Commission
Zitieren
APA
Zhou, B., Ma, Z., Wang, L., Lu, Y., Cheng, X., Jiang, Y., Wei, X., Lu, C., Cheng, S., & Lu, X. (2026). Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus. The Oncologist. https://doi.org/10.1093/oncolo/oyaf439
Vancouver
Zhou B, Ma Z, Wang L, Lu Y, Cheng X, Jiang Y, et al. Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus. The Oncologist. 2026. doi:10.1093/oncolo/oyaf439
BibTeX
@article{Zhou2026,
author = {Zhou, Bin and Ma, Zihui and Wang, Lei and Lu, Yue and Cheng, Xi and Jiang, Yabo and Wei, Xubiao and Lu, Chongde and Cheng, Shuqun and Lu, Xingsheng},
title = {Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyaf439}
}
EUVIMED